ArticleMolecular psychiatry2026
Powering the mind: deciphering the shared genetic architecture between mitochondrial DNA copy number and major psychiatric disorders.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Shared genetic architecture between ADHD and intelligence varies across ADHD subtypes.BMC medicine · 2026Article
- Dissecting the shared genetic landscape of schizophrenia and hippocampal subfields: A genome-wide cross-trait analysis.Translational psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial DNA copy number (mtDNA-CN) reflects mitochondrial function and has been associated with several psychiatric disorders. However, the shared genetic architecture between mtDNA-CN and psychiatric conditions remains largely unexplored. Utilizing the largest available genome-wide association study (GWAS) summary statistics from individuals of European ancestry, we systematically investigated the shared genetic architecture between mtDNA-CN and five major psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ). Specifically, we assessed genetic overlap at the global, regional, and variant levels. In addition, gene expression analyses were performed to identify genes whose predicted expression was associated with both mtDNA-CN and psychiatric traits. Functional enrichment analyses were conducted to characterize the biological functions underlying the shared genes. Significant global-level genetic overlap was observed between mtDNA-CN and all five psychiatric disorders. Regional analyses identified four genomic regions with high pleiotropic probability shared between mtDNA-CN and ADHD, BD, and SCZ. At the variant level, 30 lead variants were detected, corresponding to 30 independent loci jointly associated with mtDNA-CN and psychiatric traits. These loci were mapped to 305 unique genes, among which 87 genes exhibited significant associations between their predicted expression levels and both mtDNA-CN and psychiatric disorders. Functional enrichment highlighted neurodevelopmental and ubiquitin-related pathways, with significant downregulation of shared genes in key brain regions. These findings provide comprehensive evidence for shared genetic mechanisms linking mitochondrial function and psychiatric disorders, highlighting mitochondrial dysfunction as a promising target for future therapy.
Indexed as
Identifiers
41634133What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.